| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
- All
- Buy
- Hold
- Sell
| 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|
| Revenue | 8 | 10 | 16 | 24 |
| Dividend | 0.00 | 0.00 | - | - |
| Dividend Yield (in %) | - | - | - | - |
| EPS | -0.05 | 0.03 | 0.19 | 0.34 |
| P/E Ratio | -18.00 | 30.00 | 4.74 | 2.65 |
| EBIT | -1 | 0 | 3 | 5 |
| EBITDA | 0 | 1 | 3 | 5 |
| Net Profit | -1 | 0 | 2 | 3 |
| Net Profit Adjusted | 0 | 1 | 4 | - |
| Pre-Tax Profit | -1 | 0 | 3 | 5 |
| Net Profit (Adjusted) | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - |
| EPS (GAAP) | - | - | - | - |
| Gross Income | 5 | 6 | 10 | 16 |
| Cash Flow from Investing | 0 | -1 | -1 | -1 |
| Cash Flow from Operations | -1 | 0 | 2 | 4 |
| Cash Flow from Financing | 1 | 1 | 0 | 0 |
| Cash Flow per Share | - | - | - | - |
| Free Cash Flow | -1 | 0 | 2 | 3 |
| Free Cash Flow per Share | - | - | - | - |
| Book Value per Share | - | - | - | - |
| Net Debt | - | - | - | - |
| Research & Development Exp. | - | - | - | - |
| Capital Expenditure | - | - | - | - |
| Selling, General & Admin. Exp. | - | - | - | - |
| Shareholder’s Equity | 3 | 4 | 6 | 9 |
| Total Assets | 6 | 7 | 9 | 13 |
| Previous Quarter | Current Quarter | Next Quarter | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | - | - | 1 | 1 |
| Average Estimate | - | - | - | -0.050 EUR | 0.030 EUR |
| Year Ago | - | - | - | - | -0.050 EUR |
| Publish Date | - | - | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | - | - | 1 | 1 |
| Average Estimate | - | - | - | 8 EUR | 10 EUR |
| Year Ago | - | - | - | - | 8 EUR |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
*Yield of the Respective Date
Bio-Gate AG engages in the development and production of technologies and solutions for health and hygiene, primarily used in orthopedics, traumatology, and vascular surgery. The firm offers MicroSilver BG, which is pure elemental microporous silver additive with antimicrobial properties, as well as HyProtect, which is an ultrathin plasma coating that protects surfaces of medical implants against bacteria. Its technologies are also used to incorporate antimicrobial properties into cosmetics including industrial and consumer products. The company was founded on December 2, 2005 and is headquartered in Nuremberg, Germany.
Risk- Low
- Medium
- High
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
| Name | Job |
|---|---|
| Karl Richter | Chairman-Supervisory Board |
| Marc Lloret-Grau | Chief Executive Officer |
| Thomas Konradt | Director-Business Development |
| Volker Alt | Member-Supervisory Board |
| Volker Rofalski | Vice Chairman-Supervisory Board |
